Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt. Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:
MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly IndyCar Driver Living with Diabetes Helps Raise Awareness for Diabetes Treatment Options
WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda. Daly was diagnosed with Type 1 diabetes at the age of 14, and now lends his racing career to raise awareness of diabetes treatment options and innovations.
?Living with diabetes since age 14 has been a challenge, but one that I?ve always faced head on,? said Daly. ?Managing my diabetes properly has been a key to being able to live my racing dream. Diabetes should never stop you from pursuing what you want in life! Thanks to MannKind I will be able to share my story and live my dream at a higher level than ever."
?MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and successes people living with diabetes encounter on a daily basis,? says Michael Castagna, CEO of MannKind. ?Seeing someone like Conor take on a challenging sport such as IndyCar racing, while having to manage his diabetes, is an inspiration to all those living with diabetes. We are excited to be associated with Conor and Andretti Autosport for the Indy 500 and look forward to a partnership where we can help educate people on treatment options for managing their diabetes.?
As an associate sponsor of Daly at the Indy 500, MannKind is planning events and experiences that build awareness of innovation in diabetes treatment. The events and sponsorship promotion will also allow for Daly to share his story about living with diabetes.
About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
About Andretti Autosport Led by racing legend Michael Andretti, Andretti Autosport boasts a wide racing portfolio rooted in tradition and designed for success.
Under the banners of Andretti Autosport, Andretti Rallycross and Andretti Formula E, the Indianapolis-based team fields multiple entries across the IndyCar Series, Indy Lights, the FIA Formula E Championship, the GT4 America Series and Americas Rallycross. Additionally, the team competes as Walkinshaw Andretti United in the Australian Supercars category through partnership with Walkinshaw Racing and United Autosports.
The global racing enterprise boasts four IndyCar Series championships, three Indy Lights titles, one Pro Mazda championship and one USF2000 championship, and has captured victory five times at the famed Indianapolis 500-Mile Race. Additionally, the team holds two X Games Gold Medals and four U.S. rallycross championships.
To share in the Andretti story, please visit online at AndrettiAutosport.com and follow along on social media with #AllAndretti.
Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 firstname.lastname@example.org
: Milestone Payment from United Therapeutics
MannKind Receives $12.5 Million Milestone Payment from United Therapeutics WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (?TreT?) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind also announced that it filed a new shelf registration statement on Form S-3 with the Securities and Exchange Commission on March 29, 2019, which, when effective, will replace the existing shelf registration statement that expires on April 27, 2019.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) [GlobeNewswire] GlobeNewswire?February 20, 2020
WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder and MannKind?s BluHale® technology system. These data are being presented in both oral and poster presentations during the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) in Madrid Spain, February 20-22, 2020.
?We are very pleased to have the opportunity to highlight these positive results during this year?s ATTD,? stated Dr. David Kendall, Chief Medical Officer of MannKind. ?These presentations highlight original studies of Afrezza in individuals with both type 1 and type 2 diabetes, and include initial studies of Afrezza in pediatric patients. In addition to the results of clinical studies, we are pleased to disclose novel data on the use of BluHale, our Bluetooth-enabled technology for real-time profiling of inhalation effort and other parameters associated with the use of our inhaler. Collectively, these data further expand our understanding of the unique clinical profile of Afrezza, and highlight the potential use of Afrezza in children and adolescents, as well as advancing the opportunity to create connected technology for our drug delivery system.?
Highlights of the original scientific disclosures:
Preliminary data from an independent, investigator initiated study of Afrezza on the background of closed loop pump insulin delivery by means of an ?artificial pancreas? system showed that pulmonary dosing allows for titration to higher unit doses in individuals with type 1 diabetes (presented by Alfonso Galderisi MD, PhD from Yale University). Clinical use of Afrezza in adults with uncontrolled type 2 diabetes on two or more glucose lowering therapies resulted in a significant (1.6%) drop in A1c levels and a significant increase in time in range (presented by Dr. Philip Levin MD, Endocrinology, MODEL Clinical Research). Pharmacokinetics (and pharmacodynamics) of Technosphere insulin in children and adolescents ages 8-17 with type 1 diabetes showed that the ultra rapid rise in insulin concentrations corresponded with early post-prandial glucose control within the first hour post-dose, similar to what has been observed in adult patients. Two poster presentations highlighting the use of MannKind?s unique Bluetooth enabled technology for enhanced instruction on use of the Afrezza inhaler and as a tool to provide connected dose information on top of continuous glucose monitoring data.
Dr. Phillip Levin, Principal Investigator from MODEL Clinical Research in Baltimore, MD and lead author on the study of uncontrolled type 2 diabetes patients, noted that ?the addition and rapid titration of Afrezza in patients with type 2 diabetes not currently at goal using two or more glucose lowering therapies, resulted in a 1.6% reduction in A1C and significantly increased time in range as measured by CGM. Our study provides additional clarity on both dose requirements and the clinical impact of adding ultra rapid-acting Afrezza therapy in uncontrolled type 2 diabetes.?
In addition to the original scientific disclosure presented at this year?s ATTD meeting, Dr. Kendall will participate as faculty in the ?Ultra-rapid Insulin Analogues? session on Saturday, February 22, during which he will provide a current perspective on the clinical use of Afrezza, including evidence that ultra rapid-acting Afrezza can be safely and effectively titrated in fixed dose increments and that speed of insulin action may supersede dose precision for achieving post-prandial glucose control.
The full title of each of the presentations, presenting author, and the date and time of each disclosure are provided below. ORAL PRESENTATION HIGHLIGHTS
Title: Technosphere® Insulin Provides Better Early Postprandial Glucose Control Than Subcutaneous Rapid-Acting Analogue (ATTD 2020 - Saturday February 22, 2020; 8:50 ? 9:00 a.m. ? Berlin Room)
Presenter: David Kendall, MD, MannKind Corporation
ELECTRONIC POSTER PRESENTATION HIGHLIGHTS
Title: Patient Trainer Experience with BluHale® V1.0 for Proper Technosphere® Insulin Administration (ATTD 2020 ? Thursday, February 20, 2020; 8 a.m.)
Title: Safety and Pharmacokinetics of Technosphere® Insulin in Pediatric Patients (ATTD 2020 ? Thursday, February 20, 2020; 8 a.m.)
Presenter: David Kendall, MD, MannKind Corporation
Title: Insights to Improve Use of Technosphere® Insulin Provided By BluHale®, a Digital Diabetes Tool (ATTD 2020 ? Thursday, February 20, 2020; 8 a.m.)
Presenter: Benoit Adamo, MannKind Corporation
Title: Effective Treatment of Patients with Uncontrolled Type 2 Diabetes On Multiple Diabetes Medications By Adding Mealtime Ultra-rapid Technosphere® Insulin (ATTD 2020 ? Thursday, February 20, 2020; 8 a.m.)
Presenter: Philip Levin, MD, Endocrinology, MODEL Clinical Research
Title: Afrezza® Pre-meal Bolus Reduces Early Glycemic Excursion During Hybrid Closed Loop Treatment (ATTD 2020 ? Saturday, February 22, 2020; 8:30 a.m.)
Presenter: Alfonso Galderisi, MD, PhD, Yale University
About ATTD Annual Meeting The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.
About Afrezza® Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
About MannKind MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Interessanter Artikel. Dennoch erscheint mir die Aktivität bei Mannkind eher als verzweifelte Suche nach einer neuen Story und somit neuen Geldquellen. Seit Jahren hat der Laden nicht wirklich etwas geliefert, was berechtigt hoffen liese.
* Deutsche Bank Real-Time Indikationen basieren auf Preisen von der Deutschen Bank emittierten Produkten. Diese Produkte versuchen, den jeweiligen Index 1:1 zu tracken.
Die Preisstellung erfolgt börsentäglich zwischen 09:15 und 17:15.